Skip to the answer

Mycophenolate

Mycophenolate (mycophenolate mofetil) is an immune-suppressing medicine used with other medicines to help prevent rejection of a transplanted kidney, heart or liver.

Brand names CellCeptMyforticMycophenolate MofetilMyhibbin
Drug class Antimetabolite Immunosuppressant
Rx Forms 4
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 44 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 7, 2026 🚨Recall on record · 2
Other forms & routes:
Injection
Mycophenolate at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Mycophenolate is an immune-suppressing medicine taken with other anti-rejection drugs to protect a transplanted kidney, heart or liver. It is a standard part of most transplant regimens and is available as a generic, and it works by blocking an enzyme that immune cells (lymphocytes) need to make DNA, so they multiply less. Stomach upset is what most people notice, mainly diarrhea, nausea and vomiting, and it can lower blood counts, so regular blood tests are part of treatment. Its boxed warning covers pregnancy loss and serious birth defects, lymphoma and skin cancer, and serious infections, so strict pregnancy prevention, daily sun protection and prompt calls about fever or new skin changes all matter.

Clinical pearls

  • Take magnesium or aluminum antacids, and calcium-free phosphate binders like sevelamer, at least 2 hours after mycophenolate.
  • Birth control pills may work less well with mycophenolate, so add a barrier method such as condoms.
  • If a refill looks different, check it was not switched to mycophenolic acid delayed-release tablets, which are not a direct swap.
  • Do not donate blood during treatment or for 6 weeks after, and men should not donate semen until 90 days after.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Mycophenolate can cause pregnancy loss and serious birth defects, so avoid it in pregnancy if safer options exist. Females who could become pregnant need counseling about preventing and planning pregnancy.

It also raises the risk of lymphoma and other cancers, particularly skin cancer. In addition, it makes you more prone to bacterial, viral, fungal and protozoal infections, including opportunistic infections and reactivation of hepatitis B and C. These infections can lead to hospitalization or death. Watch for fever, signs of infection and new skin changes, and call your doctor promptly.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asTablet, Capsule, Oral suspension +1
Earliest FDA record1995
Companies listing it with the FDA37
FDA label last updatedAug 5, 2026
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Mycophenolate, written from its FDA label.

What Mycophenolate is used for

▾

Mycophenolate is used to prevent organ rejection, always alongside other immunosuppressants.

  • Kidney transplant, in adults and children 3 months and older
  • Heart transplant, in adults and children 3 months and older
  • Liver transplant, in adults and children 3 months and older
  • This applies to CellCept, Myhibbin and generic mycophenolate mofetil products. Injection is for intravenous use and oral forms are taken by mouth.

How Mycophenolate works

▾

Mycophenolate is converted in the body to mycophenolic acid. This blocks an enzyme (IMPDH) that lymphocytes need to build DNA and multiply. As a result, T and B immune cells grow less and respond less to the transplanted organ.

The effect slows these cells rather than destroying them, and it is reversible.

Mycophenolate dosage

▾

Mycophenolate is generally taken twice a day by mouth, or given by IV over at least 2 hours when oral use isn't possible. Food did not change total absorption but lowered the peak level. Your prescriber may reduce or pause doses if your white blood cell count drops. Follow your prescriber and label for dosing and any missed doses.

Dosing details from the FDA-approved label

From the Mycophenolate prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adults: Kidney Transplant
    • 1 g twice daily, orally or intravenously (IV) over no less than 2 h (total daily dose of 2 g)
    • Take orally on an empty stomach; may be taken with food in stable transplant patients if necessary
  • Adults: Heart Transplant
    • 1.5 g twice daily orally or IV, over no less than 2 h
  • Adults: Liver Transplant
    • 1.5 g twice daily orally or 1 g twice daily IV over no less than 2 h
  • Pediatrics: Kidney Transplant
    • 600 mg/m2 orally twice daily
    • Maximum: 2 g daily (or 10 mL of the oral suspension)
    • 3 months and older; dosing based on BSA; BSA ≥ 1.25 m2 may be dosed with capsules or tablets
  • Pediatrics: Heart Transplant
    • 600 mg/m2 orally twice daily (starting dose) up to a maximum of 900 mg/m2 twice daily
    • Maximum: 900 mg/m2 twice daily (3 g or 15 mL of oral suspension)
  • Pediatrics: Liver Transplant
    • 600 mg/m2 orally twice daily (starting dose) up to a maximum of 900 mg/m2 twice daily
    • Maximum: 900 mg/m2 twice daily (3 g or 15 mL of oral suspension)
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION ADULTS DOSAGE Kidney Transplant 1 g twice daily, orally or intravenously (IV) over no less than 2 h (2.2) Heart Transplant 1.5 g twice daily orally or IV, over no less than 2 h (2.3) Liver Transplant 1.5 g twice daily orally or 1 g twice daily IV over no less than 2 h (2.4) PEDIATRICS Kidney Transplant 600 mg/m 2 orally twice daily, up to maximum of 2 g daily (2.2) Heart Transplant 600 mg/m 2 orally twice daily (starting dose) up to a maximum of 900 mg/m 2 twice daily (3 g or 15 mL of oral suspension) ( 2.3 ) Liver Transplant 600 mg/m 2 orally twice daily (starting dose) up to a maximum of 900 mg/m 2 twice daily (3 g or 15 mL of oral suspension) ( 2.4 ) CellCept intravenous is an alternative when patients cannot tolerate oral medication. Administer within 24 hours following transplantation, until patients can tolerate oral medication, up to 14 days. (2.1) Reduce or interrupt dosing in the event of neutropenia. (2.5) See full prescribing information (FPI) for: adjustments for renal impairment and neutropenia ( 2.5 ), preparation of oral suspension. (2.6) 2.1 Important Administration Instructions Mycophenolate mofetil should not be used without the supervision of a physician with experience in immunosuppressive therapy. Mycophenolate Mofetil for O ral Suspension Mycophenolate mofetil oral dosage forms (capsules, tablets or oral suspension) should not be used interchangeably with mycophenolic acid delayed-release tablets without supervision of a physician with experience in immunosuppressive therapy because the rates of absorption following the administration of mycophenolate mofetil oral dosage forms and mycophenolic acid delayed-release tablets are not equivalent. Patients should avoid inhalation or contact of the skin or mucous membranes with the powder contained in mycophenolate mofetil for oral suspension. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water. The initial oral dose of mycophenolate mofetil should be given as soon as possible following kidney, heart or liver transplant. It is recommended that mycophenolate mofetil be administered on an empty stomach. In stable transplant patients, however, mycophenolate mofetil may be administered with food if necessary [see Clinical Pharmacology ( 12.3 )] .

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Mycophenolate side effects

▾

Common side effects in studies included:

Common side effects

  • Diarrhea
  • Vomiting
  • Nausea
  • Low white blood cell count (leukopenia)
  • Infections
  • Anemia (low red blood cells)
  • High blood pressure
  • Headache
  • Headache, swelling and pain

When to get medical help

  • Call your doctor right away for signs of infection such as fever, chills, cough or sore throat. Serious infections can lead to hospitalization or death.
  • Get help for unusual bleeding, bruising, severe tiredness or paleness. These can signal blood count problems such as neutropenia or red cell aplasia.
  • Tell your doctor about stomach pain, black or bloody stools, or vomiting blood, which can signal bleeding, ulcers or perforation.
  • Report new neurological symptoms such as confusion, weakness on one side, or trouble with balance. These can signal a rare brain infection (PML).
  • Report any new skin changes or lumps, since lymphoma and skin cancer risk is higher.
  • Seek emergency help for signs of a serious allergic reaction.
  • Tell your doctor right away if you become pregnant or suspect you are pregnant.

Mycophenolate warnings and precautions

▾
  • Pregnancy: raises the risk of first trimester pregnancy loss and birth defects of the ears, face, limbs, heart, kidneys and nervous system.
  • Cancer: higher risk of lymphoma and skin cancer, related to the intensity and length of immunosuppression.
  • Infections: including BK virus kidney problems, PML, CMV and hepatitis B or C reactivation.
  • Blood problems: neutropenia and pure red cell aplasia need blood monitoring.
  • Stomach and intestines: bleeding, ulcers and perforation can occur.
  • Acute inflammatory syndrome: a paradoxical inflammatory reaction to watch for.

Mycophenolate interactions

▾

Several medicines can change mycophenolate levels or be affected by it.

  • Magnesium or aluminum antacids and sevelamer: lower absorption, so take them at least 2 hours after mycophenolate.
  • Proton pump inhibitors: may lower levels and reduce effectiveness.
  • Cholestyramine, rifampin, cyclosporine, trimethoprim/sulfamethoxazole and some antibiotics: can lower levels.
  • Telmisartan and isavuconazole: change levels through glucuronidation.
  • Acyclovir, valacyclovir, ganciclovir, valganciclovir, probenecid: levels may rise.
  • Birth control pills: may be less effective, so add a barrier method.
  • Live vaccines: avoid.

Interactions listed in the FDA-approved label

From the Mycophenolate prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Antacids with magnesium or aluminum hydroxide: Decrease MPA systemic exposure, which may reduce mycophenolate mofetil efficacy. Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration.
  • Proton pump inhibitors (e.g., lansoprazole, pantoprazole): Decrease MPA systemic exposure, which may reduce mycophenolate mofetil efficacy. Monitor patients for alterations in efficacy when PPIs are co-administered.
  • Drugs that interfere with enterohepatic recirculation (cyclosporine A, trimethoprim/sulfamethoxazole, cholestyramine, rifampin, aminoglycoside, cephalosporin, fluoroquinolone and penicillin antimicrobials): Can decrease MPA systemic exposure, which may reduce mycophenolate mofetil efficacy. Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions.
  • Drugs modulating glucuronidation (telmisartan induces; isavuconazole inhibits): Inducers decrease MPA exposure, potentially reducing efficacy; inhibitors increase MPA exposure, which may increase the risk of adverse reactions. Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions.
  • Calcium free phosphate binders (e.g., sevelamer): Decrease MPA systemic exposure, which may reduce mycophenolate mofetil efficacy. Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil.
  • Drugs that undergo renal tubular secretion (acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir): Metabolite MPAG may compete with these drugs, which may increase their plasma concentrations and/or adverse reactions. Monitor for drug-related adverse reactions in patients with renal impairment.
  • Combination oral contraceptives: Decreased systemic exposure to levonorgestrel but did not affect ethinylestradiol, which may result in reduced contraceptive effectiveness. Use additional barrier contraceptive methods.
Read the label’s full interactions text

7 DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce mycophenolate mofetil efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. (7.1) Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended. (7.2) See FPI for other important drug interactions. (7) 7.1 Effect of Other Drugs on Mycophenolate Mofetil Table 7 Drug Interactions with Mycophenolate Mofetil that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure [see Clinical Pharmacology ( 12.3 )] , which may reduce mycophenolate mofetil efficacy. Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration. Proton Pump Inhibitors (PPIs) Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology ( 12.3 )] , which may reduce mycophenolate mofetil efficacy. Prevention or Management Monitor patients for alterations in efficacy when PPIs are co-administered with mycophenolate mofetil. Examples Lansoprazole, pantoprazole Drugs that Interfere with Enterohepatic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology ( 12.3 )] , which may reduce mycophenolate mofetil efficacy. Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿17 supplements and herbs with documented Mycophenolate interactions, ranked by severity Check Mycophenolate against a supplement or herb →

Before taking Mycophenolate

▾
  • Do not use if allergic to mycophenolate mofetil, mycophenolic acid or any ingredient.
  • Injection: not for people allergic to Polysorbate 80.
  • Avoid in HGPRT deficiency.
  • Use caution with stomach or intestinal disorders.
  • Females who could become pregnant need pregnancy tests and acceptable birth control during treatment and for 6 weeks after.
  • Male patients and their partners should use effective contraception during treatment and for at least 90 days after.
  • Breastfeeding data are limited, so discuss with your doctor.
  • Older adults: dose selection should consider reduced organ function and other medicines.

Mycophenolate overdose

▾

Too much can cause low white blood cell counts, especially neutropenia, along with stomach pain, diarrhea, nausea, vomiting and indigestion. Higher doses were linked to more stomach intolerance and blood count changes. Dialysis usually does not remove it, but bile acid sequestrants such as cholestyramine can help remove mycophenolic acid.

How your body processes Mycophenolate

▾

After oral or IV dosing, mycophenolate mofetil is fully converted to its active form, mycophenolic acid. Oral absorption was about 94% of the IV amount in healthy volunteers. Food did not change total absorption but lowered the peak level by about 40%. Mycophenolic acid is 97% bound to albumin in the blood. Blood levels were lower in the early weeks after transplant than later.

How to store Mycophenolate

▾

and Dispensing Information: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Dispense in light-resistant containers, such as the manufacturer's original containers. Store dry powder at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

17

Supplements & herbs that interact with Mycophenolate

17 supplements and herbal products have documented interactions with Mycophenolate in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 1
  • Moderate · 7
  • Minor · 9
ACTIVATED CHARCOAL Major COFFEE CHARCOAL Moderate EUROPEAN MANDRAKE Moderate GLUCOMANNAN Moderate GUAR GUM Moderate GUM ARABIC Moderate SLIPPERY ELM Moderate TRAGACANTH Moderate +9 more
Every supplement checked against Mycophenolate — ranked by severity The full interaction hub: 1 major · 7 moderate · 9 minor · every one linked to its full report. Check Mycophenolate against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Mycophenolate: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Mycophenolate — the kind of thing our pharmacy team would talk through with you at the counter.

What is this medicine for?

▾
It helps prevent your body from rejecting a transplanted kidney, heart or liver. It is always used with other immunosuppressant medicines. Adults and children 3 months and older can use it.

How should I take it?

▾
It is usually taken twice a day by mouth, or given by IV in the hospital if you can't swallow medicine at first. Follow your transplant team's directions exactly. Do not switch to mycophenolic acid delayed-release tablets unless they tell you to.

What side effects are common?

▾
Diarrhea, nausea, vomiting, low white blood cells, anemia and infections are common. High blood pressure and headaches also occur. Call your doctor if side effects are severe or you notice fever, bleeding or unusual bruising.

Can I take antacids or other medicines with it?

▾
Antacids with magnesium or aluminum, and sevelamer, should be taken at least 2 hours after mycophenolate. Acid reducers like pantoprazole or lansoprazole may lower its effect. Check with me before starting anything new.

What about pregnancy?

▾
This is very important. Mycophenolate raises the risk of pregnancy loss and serious birth defects. If you can become pregnant, you need pregnancy tests and reliable birth control during treatment and for 6 weeks after. Men and their partners should also use effective contraception during treatment and for at least 90 days after.

Do I need to protect myself from the sun?

▾
Yes. Mycophenolate raises skin cancer risk, so wear protective clothing and a broad-spectrum high-SPF sunscreen. Tell your doctor about any new skin changes.

Is Mycophenolate available over the counter?

▾
No. Mycophenolate is a prescription medicine: every Mycophenolate product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Mycophenolate first available?

▾
The earliest FDA record we hold for Mycophenolate is from 1995: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Mycophenolate was first used.

Who makes Mycophenolate?

▾
37 companies currently list Mycophenolate products in the FDA's NDC Directory, including Genentech, Inc., Remedyrepack Inc., Ascend Laboratories, LLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Mycophenolate on HelloPharmacist

📊Mycophenolate supplement interactions17 checked — ranked by severity 🌿Drug & Supplement CheckerMycophenolate vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Mycophenolate NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Mycophenolate Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Mycophenolate forms and strengths (how it comes)

Mycophenolate is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Mycophenolate inactive ingredients by manufacturer.

Tablet

By mouth
Brands CellCept Mycophenolate Mofetil
How this form is used
What it may be used for
  • Mycophenolate mofetil tablets are used to prevent rejection of kidney, heart or liver transplants, with other immunosuppressants.
Important instructions
  • Mycophenolate mofetil tablets are taken by mouth, generally twice daily.
  • Mycophenolate mofetil tablets should not be used interchangeably with mycophenolic acid delayed-release tablets.
Available strengths 1 strength
500 mg
56 FDA-listed product records ⓘ

Capsule

By mouth
Brands CellCept Mycophenolate Mofetil
How this form is used
What it may be used for
  • Mycophenolate mofetil capsules are used to prevent rejection of kidney, heart or liver transplants, with other immunosuppressants.
  • CellCept is used to prevent organ rejection in adults and children 3 months and older.
Important instructions
  • Mycophenolate mofetil capsules are taken by mouth, generally twice daily.
  • Mycophenolate mofetil capsules should not be used interchangeably with mycophenolic acid delayed-release tablets.
Available strengths 1 strength
250 mg
44 FDA-listed product records ⓘ

Oral suspension

By mouth
Brands CellCept Mycophenolate Mofetil Myhibbin
How this form is used
What it may be used for
  • Myhibbin is used to prevent rejection of kidney, heart or liver transplants, with other immunosuppressants.
  • Mycophenolate mofetil for oral suspension is used for the same transplant types in adults and children 3 months and older.
Important instructions
  • Myhibbin is taken by mouth twice daily under the supervision of a physician experienced in immunosuppressive therapy.
  • The oral suspension contains aspartame, which matters for people with phenylketonuria.
Available strengths 1 strength
200 mg/mL
29 FDA-listed product records ⓘ

Injection

By injection · Into a vein
Brands CellCept Mycophenolate Mofetil
How this form is used
What it may be used for
  • Mycophenolate Mofetil for Injection is used to prevent rejection of kidney, heart or liver transplants, with other immunosuppressants.
Important instructions
  • Mycophenolate Mofetil for Injection is given into a vein over no less than 2 hours, twice daily.
  • Mycophenolate Mofetil for Injection is an alternative when oral medicine can't be tolerated, given within 24 hours after transplant for up to 14 days.
  • Mycophenolate Mofetil for Injection should not be used in people allergic to Polysorbate 80.
Available strengths 2 strengths
500 mg/5 mL 500 mg/20 mL
23 FDA-listed product records ⓘ

Mycophenolate on the U.S. market: products, makers and brands

How Mycophenolate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

37 companies list 63 Mycophenolate product records with the FDA, mostly as tablet, capsule, oral suspension; the earliest marketing or approval year on record is 1995. Brand names on the directory include CellCept, Myfortic, Mycophenolate Mofetil and 1 more; the rest are generics.

4
Dose forms ⓘ
37
Labelers (makers, repackagers, distributors)
3
Brand names
63
FDA-listed product records ⓘ
1995
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (36) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Genentech, Inc.6%
Remedyrepack Inc.6%
Ascend Laboratories, LLC5%
Aurobindo Pharma Limited5%
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.5%
Strides Pharma Science Limited5%
Other makers68%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Mycophenolate is used (Medicaid data)

A general measure of how commonly Mycophenolate is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Mycophenolate is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

292,779
Medicaid prescriptions filled (Q1–Q4 2025)
$25.2M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Mycophenolate prescribed? Of the 1,601 medications we measure, Mycophenolate ranks #329 by Medicaid prescriptions — more than 79% of them.

Where Mycophenolate ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #329 of 1,601
#324 Clindamycin and Benzoy... 299,589 Rx #325 Ethinyl Estradiol / Et... 298,425 Rx #326 Ipratropium Oral Inhal... 298,032 Rx #327 Donepezil 295,048 Rx #328 Mirabegron 293,458 Rx #329 Mycophenolate 292,779 Rx #330 Mycophenolate Mofetil 292,779 Rx #331 Valproic Acid 292,052 Rx #332 Bumetanide 291,494 Rx #333 Sodium Bicarbonate 289,349 Rx #334 Midazolam Injection 286,843 Rx

Utilization by Mycophenolate product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

Other Mycophenolate products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)

292,779 Medicaid prescriptions (Q1–Q4 2025) 100% of Mycophenolate prescriptions shown $25.2M gross reimbursement (before rebates) ≈ $86 per prescription (gross)

Summed across the 54 of 183 listed NDC products with Medicaid activity.

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Mycophenolate, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 54 of 183 listed Mycophenolate NDCs with Medicaid activity.

Compare Mycophenolate products

A representative set of FDA-listed product records for Mycophenolate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 63 of 63 products — FDA National Drug Code Directory. See every product, package size and price: browse all 63 Mycophenolate NDCs →

Mycophenolate recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 3 Mycophenolate recalls since July 2021. Two of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class II Aug 26, 2026 · Mylan Pharmaceuticals Inc
Failed Dissolution Specifications
  • Carton label: Mycophenolate Mofetil for injection, USP, 500 mg/vial, Sterile, 4 Single Dose Vials, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505, Made in India, NDC 67457-3… Lots: Lot: 3242616, Exp. April 2027; 8220216, Exp. Nov 2027 FDA record D-0830-2026 →
Ongoing Class II Jul 2, 2026 · MYLAN PHARMACEUTICALS INC
Presence of precipitate
  • Mycophenolate Mofetil for Injection USP, 500 mg/Vial, Single Dose Vial, 4 vials per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV, 26505 USA, Made in India, NDC 67457-386… Lots: Lot #: 3241653, Exp 4/30/2027 FDA record D-0734-2026 →
Class III Oct 26, 2023 · Terminated · VistaPharm LLC
Defective Container: The adaptor does not fit into the neck of the bottle after reconstitution with water.
  • Mycophenolate Mofetil for Oral Suspension, USP, 200 mg/mL, Rx Only, bottle, Manufactured for: VistaPharm, Inc., Largo, FL 33771, USA, NDC#66689-307-08. Lots: Lot #: M23400A, M23401A, M23402A, Exp Date. 04/30/2025; M23591A, M23592A, Exp Date. 06/30/2025. FDA record D-0093-2024 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

💵 What Mycophenolate costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Capsule · Oral 250 mg $8.65 per capsule NDC details & price history
Tablet, Film Coated · Oral 500 mg $17.34 per tablet NDC details & price history
Powder, For Suspension · Oral 200 mg/mL $8.31 per mL NDC details & price history
Tablet · Oral 500 mg $0.263 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Mycophenolate brand names

Mycophenolate is sold under 4 brand names in the FDA directory — CellCept, Myfortic, Mycophenolate Mofetil, Myhibbin. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

CellCept Myfortic Mycophenolate Mofetil Myhibbin

Who makes Mycophenolate: manufacturers and labelers

37 companies list Mycophenolate products with the FDA. By number of product records, the largest are Genentech, Inc., Remedyrepack Inc., Ascend Laboratories, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Genentech, Inc. 4 Remedyrepack Inc. 4 Ascend Laboratories, LLC 3 Aurobindo Pharma Limited 3 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 3 Strides Pharma Science Limited 3 Accord Healthcare Inc. 2 Advagen Pharma Limited 2 American Health Packaging 2 Amneal Pharmaceuticals NY LLC 2 AvKARE 2 AvPAK 2 Concord Biotech Limited 2 Camber Pharmaceuticals, Inc. 2 Cardinal Health 107, LLC 2 Major Pharmaceuticals 2 Sandoz Inc 2 Strides Pharma Inc. 2 A-S Medication Solutions 1 Armas Pharmaceuticals Inc 1 Aphena Pharma Solutions - Tennessee, LLC 1 Azurity Pharmaceuticals, Inc. 1 BPI Labs LLC 1 Bryant Ranch Prepack 1

…and 13 more on the FDA NDC directory.

Sources for this Mycophenolate page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Aug 5, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Mycophenolate.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Mycophenolate after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
44
Finished products in the current FDA directory
63
Companies listing them (makers, repackagers, distributors)
37
FDA labeler codes behind them ⓘ
38
Linked representative label ⓘ
Genentech, Inc.
Linked label effective
Aug 5, 2026
Composite sections available
27
Linked SPL Set ID
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40
Linked SPL Document ID
1e79ff42-b246-420f-96af-a7b8cbf6e76e
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Genentech, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →